Glaxosmithkline Consumer Healthcare is set to heavily target the Australian market, with the company saying the business here has "huge potential".
GSK Consumer Healthcare head for Asia-Pacific, Middle East and Africa, Zubair Ahmed, has confirmed GSK will invest strongly in its local operations, boosting its staff and "advertising disproportionately" to maximise its growth potential here, according to a report in The Australian today.
He said the OTC category in Australia had doubled in the last decade to almost $9 billion.
"You have a large ageing population...consumers' knowledge and self-education is pretty high and per capita spend on health care in Australia is pretty high," he said.
Mr Zubair said GSK would look at tailoring products for Australia, similar to the creation of Panadol Osteo, which is now its biggest single item in the local market.
"The brands will be global but the formulation and packaging will be different," he said.
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Sep 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Sep 16